Pay in installments of $12.00 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
For Your Every Summer RSVP, with Code: SUMMER15
Description
Sorin of House Markov // Sorin, Ravenous Neonate [Modern Horizons 3]Set: Modern Horizons 3 Type: Legendary Creature Human Noble Legendary Planeswalker Rarity: Mythic Lifelink Extort (Whenever you cast a spell, you may pay (W B). If you do, each opponent loses 1 life and you gain that much life.) At the beginning of your postcombat main phase, if you gained 3 or more life this turn, exile Sorin of House Markov, then return him to the battlefield transformed under his owner's control. Reverse Type: Legendary
| Set: | Modern Horizons 3 |
| Type: | Legendary Creature — Human Noble // Legendary Planeswalker |
| Rarity: | Mythic |
Lifelink
Extort (Whenever you cast a spell, you may pay (W/B). If you do, each opponent loses 1 life and you gain that much life.)
At the beginning of your postcombat main phase, if you gained 3 or more life this turn, exile Sorin of House Markov, then return him to the battlefield transformed under his owner's control.
Extort (Whenever you cast a spell, you may pay (W/B). If you do, each opponent loses 1 life and you gain that much life.)
At the beginning of your postcombat main phase, if you gained 3 or more life this turn, exile Sorin of House Markov, then return him to the battlefield transformed under his owner's control.
| Reverse Type: | Legendary Planeswalker — Sorin |
Extort (Whenever you cast a spell, you may pay (W/B). If you do, each opponent loses 1 life and you gain that much life.)
[+2]: Create a Food token.
[-1]: Sorin, Ravenous Neonate deals damage equal to the amount of life you gained this turn to any target.
[-6]: Gain control of target creature. It becomes a Vampire in addition to its other types. Put a lifelink counter on it if you control a white permanent other than that creature or Sorin.
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
4.4 ★★★★★
Based on 28 reviews
Sort
Product Reviews
★★★★★ 5
Comfortable and loving the slip-in feature!
Size: 10.5 X-Wide, Color: Navy
These slip-in shows are so convenient and comfortable, and have worked well for several months now. It's important to make sure that the size is not too small, as it can make the shoes feel like they will fall off. With the right fit, these shoes are very comfortable. The material breathes well and seems to be durable.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on January 1, 2026
★★★★★ 5
Great shoes
Size: 10.5, Color: Black/White
Very comfortable shoes, easy to slip into, I tried to find these 2 years back but no one had them
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on January 8, 2026
★★★★★ 5
great
Size: 10.5, Color: Black/White
these are the best shoes ever better then diabetic shoes
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 2, 2026
★★★★★ 5
Sketchers can’t be beat.
Size: 9, Color: Navy
What can I say? I love sketcher slipin's. They are comfortable and so easy to slip on and off. I have three pairs and would recommend them to anyone who has trouble putting their shoes on and off. They are well made and are very durable. They come in a variety of styles.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 23, 2025
★★★★★ 4
Great feeling shoe just blah in style
Size: 9.5, Color: Black/Black
Great fit and feel walking but just lackluster in style. Kind of black blah.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on December 10, 2025